This review provides a critical overview of the current potential of nanotechnology to solve problems associated with overcoming biological barriers to deliver novel cancer therapies, including small cytotoxic molecules and biological drugs such as RNA or mAbs. Nanodelivery strategies, including active and passive  targeting, are benefitting from significant progress in drug discovery, molecular  biology, and biomaterials advances.

Full article